127 related articles for article (PubMed ID: 37220310)
1. Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer.
Ma L; Li Y; Luo R; Wang Y; Cao J; Fu W; Qian B; Zheng L; Tang L; Lv X; Zheng L; Liang G; Chen L
J Med Chem; 2023 Jun; 66(11):7438-7453. PubMed ID: 37220310
[TBL] [Abstract][Full Text] [Related]
2. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.
Kataoka Y; Mukohara T; Tomioka H; Funakoshi Y; Kiyota N; Fujiwara Y; Yashiro M; Hirakawa K; Hirai M; Minami H
Invest New Drugs; 2012 Aug; 30(4):1352-60. PubMed ID: 21655918
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2.
Du G; Jiang J; Wu Q; Henning NJ; Donovan KA; Yue H; Che J; Lu W; Fischer ES; Bardeesy N; Zhang T; Gray NS
Angew Chem Int Ed Engl; 2021 Jul; 60(29):15905-15911. PubMed ID: 33915015
[TBL] [Abstract][Full Text] [Related]
4. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
5. Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in
Sase H; Nakanishi Y; Aida S; Horiguchi-Takei K; Akiyama N; Fujii T; Sakata K; Mio T; Aoki M; Ishii N
Mol Cancer Ther; 2018 Oct; 17(10):2217-2225. PubMed ID: 30045926
[No Abstract] [Full Text] [Related]
6. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Goyal L; Shi L; Liu LY; Fece de la Cruz F; Lennerz JK; Raghavan S; Leschiner I; Elagina L; Siravegna G; Ng RWS; Vu P; Patra KC; Saha SK; Uppot RN; Arellano R; Reyes S; Sagara T; Otsuki S; Nadres B; Shahzade HA; Dey-Guha I; Fetter IJ; Baiev I; Van Seventer EE; Murphy JE; Ferrone CR; Tanabe KK; Deshpande V; Harding JJ; Yaeger R; Kelley RK; Bardelli A; Iafrate AJ; Hahn WC; Benes CH; Ting DT; Hirai H; Getz G; Juric D; Zhu AX; Corcoran RB; Bardeesy N
Cancer Discov; 2019 Aug; 9(8):1064-1079. PubMed ID: 31109923
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells.
Grygielewicz P; Dymek B; Bujak A; Gunerka P; Stanczak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K; Zdzalik D
Gastric Cancer; 2016 Jan; 19(1):53-62. PubMed ID: 25407459
[TBL] [Abstract][Full Text] [Related]
8. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification.
Kim ST; Jang HL; Lee SJ; Lee J; Choi YL; Kim KM; Cho J; Park SH; Park YS; Lim HY; Yashiro M; Kang WK; Park JO
Mol Cancer Ther; 2014 Nov; 13(11):2527-36. PubMed ID: 25249557
[TBL] [Abstract][Full Text] [Related]
10. From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor.
Turner LD; Trinh CH; Hubball RA; Orritt KM; Lin CC; Burns JE; Knowles MA; Fishwick CWG
J Med Chem; 2022 Jan; 65(2):1481-1504. PubMed ID: 34780700
[TBL] [Abstract][Full Text] [Related]
11. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
12. Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors.
Yamaguchi H; Takanashi M; Yoshida N; Ito Y; Kamata R; Fukami K; Yanagihara K; Sakai R
Cancer Sci; 2014 May; 105(5):528-36. PubMed ID: 24612061
[TBL] [Abstract][Full Text] [Related]
13. RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.
Subbiah V; Sahai V; Maglic D; Bruderek K; Touré BB; Zhao S; Valverde R; O'Hearn PJ; Moustakas DT; Schönherr H; Gerami-Moayed N; Taylor AM; Hudson BM; Houde DJ; Pal D; Foster L; Gunaydin H; Ayaz P; Sharon DA; Goyal L; Schram AM; Kamath S; Sherwin CA; Schmidt-Kittler O; Jen KY; Ricard F; Wolf BB; Shaw DE; Bergstrom DA; Watters J; Casaletto JB
Cancer Discov; 2023 Sep; 13(9):2012-2031. PubMed ID: 37270847
[TBL] [Abstract][Full Text] [Related]
14. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.
Byron SA; Chen H; Wortmann A; Loch D; Gartside MG; Dehkhoda F; Blais SP; Neubert TA; Mohammadi M; Pollock PM
Neoplasia; 2013 Aug; 15(8):975-88. PubMed ID: 23908597
[TBL] [Abstract][Full Text] [Related]
15. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.
Kunii K; Davis L; Gorenstein J; Hatch H; Yashiro M; Di Bacco A; Elbi C; Lutterbach B
Cancer Res; 2008 Apr; 68(7):2340-8. PubMed ID: 18381441
[TBL] [Abstract][Full Text] [Related]
16. Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β.
Lau WM; Teng E; Huang KK; Tan JW; Das K; Zang Z; Chia T; Teh M; Kono K; Yong WP; Shabbir A; Tay A; Phua NS; Tan P; Chan SL; So JBY
Mol Cancer Ther; 2018 Jan; 17(1):232-242. PubMed ID: 28978722
[TBL] [Abstract][Full Text] [Related]
17. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.
Kim SY; Ahn T; Bang H; Ham JS; Kim J; Kim ST; Jang J; Shim M; Kang SY; Park SH; Min BH; Lee H; Kang WK; Kim KM; Park W; Lee J
Oncotarget; 2017 Feb; 8(9):15014-15022. PubMed ID: 28122360
[TBL] [Abstract][Full Text] [Related]
19. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
[TBL] [Abstract][Full Text] [Related]
20. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]